Hypothyroidism During Antithyroid Drug Treatment with Methimazole is a Favorable Prognostic Indicator in Patients with Graves' Disease
| Autor: | Dong Woo Kim, Young Kwang Choo, Won Sang Yoo, Hyun-Kyung Chung |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Drug endocrine system medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism Graves' disease media_common.quotation_subject Thyrotropin Disease Gastroenterology Methimazole Endocrinology Antithyroid Agents Hypothyroidism Internal medicine medicine Exophthalmos Humans Euthyroid In patient Autoantibodies Retrospective Studies media_common biology Goiter business.industry Retrospective cohort study Middle Aged Prognosis medicine.disease Graves Disease Thyroxine biology.protein Female Antibody business hormones hormone substitutes and hormone antagonists Immunoglobulins Thyroid-Stimulating medicine.drug |
| Zdroj: | Thyroid. 20:949-954 |
| ISSN: | 1557-9077 1050-7256 |
| DOI: | 10.1089/thy.2009.0126 |
| Popis: | A major problem with antithyroid drug (ATD) therapy in Graves' disease is the high relapse rate. Therefore, clinicians have sought prognostic indicators of permanent remission. Suppression of serum thyrotropin (TSH) when ATD therapy is stopped carries a poor prognosis, but little is known regarding the significance of elevated serum TSH concentrations in the course of ATD therapy. The objective of this study was to determine if elevated serum TSH concentrations during methimazole (MMI) therapy is associated with a favorable long-term prognosis.We retrospectively studied patients with Graves' disease who were initially on MMI, in whom this drug was stopped because they had undetectable thyroid-stimulating antibodies (TSAbs) or were euthyroid after at least 24 months on MMI treatment. A strategy of high MMI doses plus T4 was not used in these patients. We identified 40 patients with elevated serum TSH concentration (10 microIU/mL) during MMI therapy (H-TSH group). Eighty-five percent of the H-TSH group had negative tests for TSAb. The H-TSH group was sex- and age-matched with 37 patients who had similar selection criteria, but did not have elevated serum TSH concentration during MMI therapy (N-TSH group). The H-TSH and N-TSH groups were similar in gross thyroid size, percentage of patients with exophthalmos, serum free thyroxine, duration of MMI treatment, TSAb status, duration that their TSAb tests remained negative, and thyroid peroxidase antibody titers. The patients were followed for 24 months after stopping MMI.In the H-TSH group, MMI-associated hypothyroidism typically occurred after 7-8 months of treatment with daily doses of 10-15 mg MMI. No patient had severe symptoms of hypothyroidism. The percentage of patients in remission at 6, 12, and 24 months after discontinuation of MMI was 90.0, 87.5, and 85.0, respectively, in the H-TSH group and 70.3, 67.6, and 54.1, respectively, in the N-TSH group (p 0.05 for the comparison of groups at 6 and 12 months and p 0.001 for comparison of the groups at 24 months).In patients with Graves' disease who are treated with MMI for at least 2 years and become euthyroid, the occurrence of elevated serum TSH concentrations during MMI treatment is a favorable indicator for long-term remission and is independent of multiple other factors including TSAb status, duration of MMI treatment, and gross parameters of goiter size. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|